{
    "code": "02022473",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02022473",
    "time": "2024-04-04 19:34:48",
    "許可證字號": "衛署藥輸字第022473號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "118\/05\/04",
    "發證\/登錄日期": "113\/03\/22",
    "許可證\/登錄種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA00202247306",
    "中文品名": "抗癌妥靜脈輸注濃縮液",
    "英文品名": "CAMPTO CONC. SOLUTION FOR I.V. INFUSION",
    "適應症": "1. 晚期性大腸直腸癌之第一線治療藥物：\r\n(1)與5-FU和folinic acid合併，使用於未曾接受過化學治療之病人。\r\n(2)單獨使用於曾接受5-FU療程治療無效之病人。\r\n(3)與cetuximab併用，治療曾接受含irinotecan之細胞毒性療法治療失敗且具有上皮生長因子接受體(EGFR)表現型KRAS野生型轉移性大腸直腸癌病人。\r\n(4)與5-fluorouracil、folinic acid及bevacizumab合併治療，做為轉移性大腸癌或直腸癌病人的第一線治療藥物。\r\n(5)與capecitabine合併治療，做為轉移性大腸直腸癌病人的第一線治療藥物。\r\n(6)與5-fluorouracil、leucovorin及oxaliplatin合併治療(FOLFIRINOX)，做為轉移性胰臟癌之第一線治療藥物。\r\n2. 做為不可切除局部晚期及復發\/轉移性胃癌之治療藥物。",
    "劑型": "270注射劑",
    "包裝": "各100支以下盒裝 2毫升、5毫升及15毫升塑膠小瓶裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "IRINOTECAN HYDROCHLORIDE TRIHYDRATE",
    "限制項目": "02輸　入",
    "申請商名稱": "輝瑞大藥廠股份有限公司",
    "申請商地址": "台北市信義區松仁路100號42、43樓",
    "主製造廠": [
        {
            "製造廠名稱": "PFIZER (PERTH) PTY LIMITED",
            "製造廠廠址": "TECHNOLOGY PARK,15 BRODIE HALL DRIVE,BENTLEY WA 6102,AUSTRALIA.",
            "製造廠公司地址": "",
            "製造廠國別": "AUSTRALIA",
            "製程": "製造、包裝"
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "久裕企業股份有限公司",
            "製造廠廠址": "桃園市桃園區大林里興邦路43巷2-1號4樓、3樓、1樓A區",
            "製造廠公司地址": "",
            "製造廠國別": "",
            "製程": "二級包裝廠(委託貼標及置入仿單)"
        }
    ],
    "CCC號列": "30049071005 抗癌藥Anti-cancer preparations",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200037710",
            "成分名稱": "IRINOTECAN HYDROCHLORIDE TRIHYDRATE",
            "含量描述": "",
            "含量": "20.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "Campto_藥物外觀-104-09-22(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022473&Seq=001&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "4. Campto LLD France 20210611-2-111-06-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022473&Seq=017&Type=9"
        },
        {
            "title": "Campto -110-04-23(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022473&Seq=018&Type=8"
        },
        {
            "title": "Campto 100mg.5ml-109-06-04(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022473&Seq=017&Type=8"
        },
        {
            "title": "Campto conc solution for IV infusion-108-09-18(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022473&Seq=016&Type=8"
        },
        {
            "title": "Campto_外盒包裝-104-09-22(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022473&Seq=015&Type=8"
        }
    ]
}